Jaypirca Approved: New Leukemia & Lymphoma Treatment Option

“`html

FDA expands Approval of Pirtobrutinib for Relapsed or Refractory Leukemia

The food and Drug Administration has broadened the approval of pirtobrutinib, offering a new treatment option for adults battling relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This expanded indication builds upon the drug’s 2023 accelerated approval, now encompassing patients previously treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.

Did you know? – CLL and SLL are slow-growing blood cancers affecting lymphocytes, a type of white blood cell. Relapsed or refractory disease means the cancer returned after treatment or didn’t respond initially.

the FDA’s decision stems from compelling data presented in the BRUIN-CLL-321 trial, a randomized, open-label study involving 238 patients who had previously undergone treatment for CLL or SLL with a covalent BTK inhibitor. Researchers assigned participants in a 1:1 ratio to receive either pirtobrutinib or a regimen chosen by investigators – rituximab plus idelalisib, or bendamustine. Notably, patients in the control group were allowed to transition to pirtobrutinib monotherapy if their initial treatment showed signs of disease progression.

Results demonstrated a notable advancement in progression-free survival (PFS) among patients receiving pirtobrutinib monotherapy, with a hazard ratio (HR) of 0.58 (95% confidence interval [CI], 0.38-0.89) compared to the investigator’s choice group. Approximately 42% – 50 of 119 patients – in the investigator’s choice arm ultimately crossed over to receive pirtobrutinib monotherapy during the study. an updated analysis, with a median follow-up of 19.8 months, revealed an overall survival (OS) HR of 1.09 (95% CI, 0.68-1.75).

pro tip: – Progression-free survival (PFS) measures the length of time during a study that participants live with the disease not getting worse. A lower hazard ratio indicates better outcomes.

Pirtobrutinib, marketed as Jaypirca by Eli Lilly and Co., carries warnings and precautions related to potential infections, hemorrhage, cytopenias, cardiac arrhythmias, secondary primary malignancies, hepatotoxicity, and embryo-fetal toxicity. The recommended dosage is 200 mg administered orally once daily, continuing until disease progression or the emergence of unacceptable toxicity.

This approval represents a significant step forward in the treatment landscape for patients with CLL and SLL who have fatigued other options,offering a potentially effective therapy for a challenging disease.

Reader question: – For patients who have tried multiple BTK inhibitors,what makes pirtobrutinib different and potentially more effective? What are the biggest challenges to access?

Why: The FDA expanded the approval of pirtobrutinib to provide a treatment option for adults with relapsed or refractory CLL or SLL who have previously been treated with a covalent BTK inhibitor. Who: This approval benefits adults diagnosed with these specific types of leukemia who have not responded to, or whose disease has returned after, treatment with other BTK inhibitors. What: Pirtobrutinib (Jaypirca) is a medication that targets Bruton tyrosine kinase (BTK), a protein involved in the growth of leukemia cells. The BRUIN-CLL-321 trial demonstrated improved progression-free survival with pirtobrutinib compared to standard treatments. How did it end?: The BRUIN-CLL-321 trial showed a hazard ratio of 0.58 for progression-free survival, indicating a significant benefit for patients receiving pirtobrutinib. while overall survival data showed a hazard ratio of 1.09, the study continues to follow patients for